Corporate presentation
Logotype for Autolus Therapeutics plc

Autolus Therapeutics (AUTL) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Autolus Therapeutics plc

Corporate presentation summary

16 Nov, 2026

Strategic position and manufacturing

  • AUCATZYL is the approved obe-cel product for adult r/r B-ALL; pediatric ALL, lupus nephritis and progressive MS are development opportunities.

  • Manufacturing success rate exceeded 90%, with fast, reliable product delivery and no capacity limitations reported in the first launch year.

  • Manufacturing priorities include process and operating-model optimization, more automation, and a next-generation platform targeting step-changes in cost and capacity.

Commercial performance

  • Q3 2026 net product revenue was $41.2M, up 95% vs Q3 2025; 9M 2026 revenue was $113.1M, up 122% vs 9M 2025.

  • FY 2026 net product revenue is expected to meet or exceed $150M, the upper end of prior guidance; 90 U.S. authorized treatment centers were listed.

  • Q3 2026 gross margin was 57% and YTD margin was 44%; peak gross margin expectation is 65–70%, supported by higher volumes and cost efficiencies.

  • Growth drivers include demand at existing U.S. centers, new centers coming online, UK sales, and additional ROCCA real-world data expected in Dec 2026.

Clinical evidence and pipeline

  • In FELIX, overall remission was 77% across 127 patients; Grade ≥3 CRS was 2% and Grade ≥3 ICANS was 7%, with no high-grade events among patients with <5% blasts at lymphodepletion.

  • FELIX follow-up showed 46.0% overall survival probability at 24 months; median duration of response was 42.6 months at the last data cut, with more than half of patients in remission at 24 months.

  • ROCCA real-world data included 91 patients receiving both infusions and 84 evaluable at Day 28; reported safety included no high-grade CRS and 3% high-grade ICANS.

  • CATULUS pediatric Phase 1 data showed 95.5% ORR and 90.9% CR at median follow-up of 8.8 months; Phase 2 is enrolling, with data expected by end-2027.

  • CARSLYLE’s 50M-cell cohort achieved DORIS in 5/6 patients and complete renal response in 3/6; LUMINA Phase 2 is enrolling 30 severe, refractory LN patients, with data anticipated in 2028.

  • BOBCAT is a Phase 1 obe-cel study in progressive MS; preliminary data are targeted for Q1 2027 and full Phase 1 data for 2H 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Autolus Therapeutics